Designing new antibiotics to combat antibiotic resistance
Computational de novo design of macrocyclic type I Signal Peptidase inhibitors
This study is working on creating new antibiotics to help fight stubborn infections that don't respond to current treatments, using smart computer techniques to target a key part of bacteria that helps them survive.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10889835 on NIH RePORTER |
What this research studies
This research focuses on developing new antibiotics to address the growing problem of antibiotic resistance. By using advanced computational methods, including deep learning and high-throughput chemical synthesis, the team aims to create inhibitors targeting a specific bacterial enzyme called type I signal peptidase. This enzyme is crucial for the proper functioning of many bacteria, and the research will explore how to design effective inhibitors that can work against a broad range of bacterial strains. Patients may benefit from new antibiotic treatments that are effective against resistant infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients suffering from infections caused by antibiotic-resistant bacteria.
Not a fit: Patients with infections that are already effectively treated by existing antibiotics may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of new antibiotics that are effective against antibiotic-resistant infections.
How similar studies have performed: Other research has shown promise in using computational methods to design new antibiotics, indicating that this approach has potential for success.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Bhardwaj, Gaurav — University of Washington
- Study coordinator: Bhardwaj, Gaurav
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.